L3VLUP
ProSign in

PTGX · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PTGXVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PTGX
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterPTGXVRTX
Q3 20201 holders, $54m31 holders, $21.9bn
Q4 20202 holders, $60m30 holders, $18.4bn
Q1 20212 holders, $87m31 holders, $15.4bn
Q2 20212 holders, $156m30 holders, $12.7bn
Q3 20214 holders, $130m35 holders, $10.1bn
Q4 20214 holders, $169m28 holders, $12.4bn
Q1 20223 holders, $110m23 holders, $16.1bn
Q2 20225 holders, $67m25 holders, $18.1bn
Q3 20223 holders, $53m22 holders, $18.4bn
Q4 20225 holders, $52m28 holders, $18.4bn
Q1 20234 holders, $116m26 holders, $21.4bn
Q2 20235 holders, $171m27 holders, $24.7bn
Q3 20232 holders, $109m33 holders, $24.3bn
Q4 20232 holders, $191m32 holders, $28.6bn
Q1 20245 holders, $248m31 holders, $29.8bn
Q2 20243 holders, $262m29 holders, $33.4bn
Q3 20243 holders, $286m27 holders, $33.5bn
Q4 20244 holders, $253m26 holders, $28.5bn
Q1 20254 holders, $354m21 holders, $35.4bn
Q2 20255 holders, $425m21 holders, $32.3bn
Q3 20258 holders, $790m22 holders, $25.9bn
Q4 202510 holders, $1.3bn26 holders, $31.8bn
Q1 20269 holders, $1.8bn25 holders, $31.8bn
Q2 20267 holders, $1.9bn26 holders, $34.6bn
PTGX

Protagonist Therapeutics Inc

Holders
10
Reported value
$1.3bn
Buyers
14
Sellers
14

Breadth 0 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PTGX (4)

Farallon Capital Management LLC, Holocene Advisors LP, Polen Capital Management LLC, Soros Fund Management LLC

Only VRTX (20)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Invesco Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →